Vancomycin Derivative Inactivates Carbapenem-Resistant
Acinetobacter baumannii
/ drug effects
Animals
Anti-Bacterial Agents
/ chemical synthesis
Autophagy
/ drug effects
Biofilms
/ drug effects
Female
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Mice, Inbred BALB C
Microbial Sensitivity Tests
Vancomycin
/ analogs & derivatives
beta-Lactam Resistance
/ drug effects
Journal
ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906
Informations de publication
Date de publication:
17 04 2020
17 04 2020
Historique:
pubmed:
21
3
2020
medline:
23
1
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Vancomycin is a standard drug for the treatment of multidrug-resistant Gram-positive bacterial infections. Albeit, development of resistance (VRE, VRSA) and its inefficacy against persistent infections is a demerit. It is also intrinsically inactive against Gram-negative bacteria. Herein, we report a vancomycin derivative, VanQAmC
Identifiants
pubmed: 32195571
doi: 10.1021/acschembio.0c00091
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM